ACE 393

Drug Profile

ACE 393

Alternative Names: ACE-393; Campylobacter jejuni vaccine - Zymenex

Latest Information Update: 21 Mar 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACE BioSciences
  • Developer ACE BioSciences; Naval Medical Research Center
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Campylobacter infections

Most Recent Events

  • 21 Mar 2014 Discontinued - Phase-II for Campylobacter infections in USA & Phase I for Campylobacter infections in France (IM)
  • 18 Jan 2011 No development reported - Phase-II for Campylobacter infections in USA (IM)
  • 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top